Moderna's Q3 Sales, 2021 Guidance Hit By Coronavirus Vaccine Supply Hiccups
Quarterly Sales Miss Expectations By $1bn
Executive Summary
The company sees better times ahead for mRNA-1273, with supply contracts raising guidance for 2022, not to mention progress in its non-COVID-19 pipeline.
You may also be interested in...
COVID-19 Products Had Strong 2021, But Omicron Casts Shadow Over 2022
Evidence that the new variant dulls drugs and vaccines’ efficacy creates uncertainty for 2022, but new products are in the wings.
Comirnaty Gives Booster Shot To Pfizer Q3 Sales
The company increased its guidance for sales of the COVID-19 vaccine again, to $36bn, though many other products’ sales were close to or below analyst expectations.
With Pfizer EUA For 5-11 And Moderna Delay For Adolescents, US FDA Walks Myocarditis Tightrope
COVID vaccine safety concerns from international analyses will force sponsors and FDA to again confront the challenge of how to make bad news for one shot not turn into bad news for all.